Abstract Nine months of daily isoniazid is efficacious in treating latent M. tuberculosis infection, but completion rates are low, limiting treatment effectiveness. In 2011, three important studies were published involving novel regimens for the treatment of latent M. tuberculosis infection. At least 36 months of isoniazid was more effective than 6 months of isoniazid in one study, but not in another-both of which were conducted among tuberculin skin test positive HIVinfected adults living in high tuberculosis incidence settings.
Introduction
Persons infected with both human immunodeficiency virus (HIV) and M. tuberculosis develop active tuberculosis (TB) at much higher rates than HIV-uninfected persons, with an annual incidence of 8-10 % among those with untreated HIV infection [1•, 2] . The World Health Organization (WHO) estimated that in 2010 approximately 13 % of tuberculosis cases worldwide occurred in HIV-infected individuals [3] . Thus, prevention of TB disease is critical. A recent Cochrane review found that treatment of latent M. tuberculosis infection (LTBI) in HIV-infected persons with a positive tuberculin skin test prevents tuberculosis and improves survival [4] . However, acceptance and completion of isoniazid (INH) preventive therapy is low in both HIV-uninfected and HIV-infected persons [5, 6] . The World Health Organization (WHO) recommends screening all persons with HIV for four symptoms: current cough, fever, weight loss, and night sweats. If these symptoms are absent, INH preventive therapy is recommended even in the absence of skin testing [7] . Challenges to this strategy include the lack of proven effectiveness of INH in tuberculin skin test negative persons. Further, it is critically important to identify other safe, efficacious treatment regimens that have high completion rates and therefore high effectiveness.
The standard recommended treatment for LTBI is 9 months of daily INH. Completion rates of INH are lower than with shorter regimens [5, 6, [8] [9] [10] . Given this, several recent studies have examined possible alternative regimens for the treatment of LTBI, evaluating the optimal duration of therapy, tolerability, efficacy, durability of protective effect, and cost. Here we review the literature from the past year (2011) on treatment of M. tuberculosis in HIV-infected persons.
Recent Studies of Latent M. tuberculosis Treatment
In 2011, three important studies of regimens to treat LTBI were published. All three studies included HIV-infected adults, and are included in this review. Another study assessed a strategy of prolonged isoniazid therapy among HIV-infected and HIV-uninfected but exposed infants [11] . That study is not included in this review because it evaluated a general strategy rather than a regimen directed against LTBI. The characteristics of all four studies are described in Table 1 .
Six vs. 36 Months of INH, Botswana
Because of concerns that the protective effect of a 6-month course of INH may wane after treatment completion in areas of high tuberculosis prevalence (and possible M. tuberculosis re-infection) [12, 13] , a study of 6 versus 36 months of INH was conducted among HIV-infected adults in Botswana [14••] .
This randomized, placebo-controlled, double-blind trial enrolled 1995 HIV-infected adults from 2004 to 2009; persons were eligible for inclusion regardless of tuberculin skin test status. Participants were enrolled into one of two groups: 1) the continued treatment group, which consisted of open-label INH for 6 months, followed by 30 additional months of INH, or 2) the control group, which consisted of 6 months of INH followed by 30 months of placebo. TB incidence was 0.72 % per year in the group randomized to 36 months of INH vs 1.26 % per year in persons receiving 6 months of INH (HR 0.57, 95 % CI 0.33-0.99, P00.047). Approximately 1 year after study enrollment, TB incidence increased in the control group compared to persons who continued to receive INH. The protective effect of continued INH was greatest among persons with a positive tuberculin skin test; the TB incidence was 1.6 % in the 36INH group vs. 6.0 % in the 6INH group, demonstrating a 74 % reduction in TB incidence. There was no significant protective effect of 36 months of INH among tuberculin skin testnegative persons. Notably, among tuberculin skin test positive persons there was a three-fold lower mortality risk for those who received 36INH compared to 6INH, and additional protective benefit with antiretroviral therapy, as described in detail below. Participants were randomized to one of 4 groups: 1) rifapentine 900 mg plus isoniazid 900 mg once weekly for 12 weeks, 2) rifampin (RIF) 600 mg plus isoniazid 900 mg twice weekly for 12 weeks, 3) isoniazid 300 mg daily for the duration of the study (≤6 years, continuous INH), or 4) isoniazid 300 mg daily for 6 months (6INH; control group). Those in the rifapentine/INH group and rifampin/INH group received directly-observed therapy (DOT) in the clinic; the INH-only groups did not. Of note, this trial was designed to assess the potential superiority of the three investigational regimens compared to the control regimen (6INH).
Incidence rates of TB per 100 person-years were 2.0 in the rifapentine/INH group, 2.0 in the RIF/INH group, 1.4 in the continuous INH group, and 1.9 in the 6INH group; none of these rates were statistically significantly different, and none were superior to 6INH. In a post-hoc as-treated analysis there was a 58 % lower risk of TB or death in the continuous INH group compared to the group that received 6 months of INH, but the tuberculosis risk increased markedly after discontinuation of continuous INH. There was a trend towards more adverse events in the continuous INH group when compared with the two rifamycin-containing regimens, and adherence rates were higher for those taking the 12-week regimens. Among those who developed TB, there were 2 cases of rifampin resistance in the rifapentine/ INH arm, none in the RIF/INH arm, and one in the continuous INH arm.
Three Months of Once-Weekly Rifapentine and INH Versus 9 Months INH, U.S, Canada, Brazil, and Spain
In this prospective non-inferiority trial, participants were randomized to open-label, directly-observed, onceweekly rifapentine 900 mg plus INH (max dose 900 mg) for 12 weeks (combination-therapy group) vs. selfadministered INH 300 mg daily for 9 months (control group) [16••] . Subjects were at high risk for TB; individuals had to have been a close contact to a case of TB and have a positive tuberculin skin test, have HIV infection and a positive tuberculin skin test or close contact, have conversion of tuberculin skin test from negative to positive, or chest radiograph changes consistent with previous TB disease. The study took place from 2001 to 2010. Overall, a small proportion of the study population was HIV-infected; 100 (2.7 %) in the INH group and 105 (2.6 %) in the combination therapy group. Three months of once-weekly rifapentine plus INH was at least as effective as 9 months of INH, with TB rates in the former group half that of the 9INH group. Completion rates were 82 % in the combination therapy group and 69 % in the 9INH group (P<0.001). Enrollment was extended among HIV-infected persons to obtain additional tolerability and effectiveness data in this population; results are pending. • Adverse events were similar in both groups Madhi et al. [11] Randomized to:
• 548 HIV-infected and 804 HIV-uninfected infants (exposed to HIV during perinatal period)
• RCT, Taken together, the information provided in these three studies is important, but must be placed in the context of several other issues. We discuss these issues below.
Role of Antiretroviral Therapy
It has previously been shown that antiretroviral therapy decreases the incidence of tuberculosis among HIVinfected persons in countries with high or low TB incidence [17] [18] [19] ; in a meta-analysis antiretroviral therapy reduced TB incidence by 67 % [20] . This finding is further supported by the studies discussed above. Notably, in the Botswana trial, only 2 % of participants were on antiretroviral therapy at enrollment and 45 % started antiretroviral therapy during the course of the study [14••] . Persons receiving antiretroviral therapy had a lower risk of TB; for those with a positive tuberculin skin test, the greatest protective effect was seen among those who received both antiretroviral therapy and continuous INH. Interestingly, persons with negative tuberculin skin tests had lower TB risk with antiretroviral therapy, but not with continuous INH [14••] . This reduction in TB disease with antiretroviral therapy regardless of tuberculin skin test result may be due to an improved ability to control LTBI, including after recent TB exposure [21] . Antiretroviral therapy is also associated with lower TB recurrence rates, and decreased mortality [21] .
For the benefits of antiretroviral therapy on TB incidence to fully be realized, further scale-up of ART is needed, but limitations on resources will no doubt diminish the feasibility of widespread test-and-treat initiatives. There are ongoing trials investigating the use of INH preventive therapy given in conjunction with antiretroviral therapy or of INH preventive therapy given prior to starting antiretroviral therapy [22, 23] . Regardless, it is clear that neither antiretroviral therapy nor INH preventive therapy alone is sufficient; best results for reduction in TB incidence has been shown when the two are implemented in concert [24, 25] .
Safety and Tolerability
Given that persons with LTBI are not sick or able to transmit disease, it is paramount that treatment regimens have minimal adverse events. This is particularly important in HIVinfected persons, who may receive several concomitant medications, and therefore be subject to drug-drug interactions and pharmacokinetic variability.
Six months of INH preventive therapy appears to be largely safe in HIV-infected persons. In the trial comparing 36 vs. 6 months of INH, overall rates of adverse events and death were similar in both groups. However, for the subpopulation of those with negative tuberculin skin tests who received 36 months of INH, there were significantly more deaths-though most of these deaths were not related to INH [14••] . In the South African trial, in those who were tuberculin skin test positive and received continuous INH, adverse events were more common compared to the other, shorter regimens, with 28 % of persons in the continuous INH group experiencing grade 3 or 4 elevations in liver enzymes during the treatment phase, compared to 5.5 % in the 6INH arm [15••] .
Rifamycin-containing regimens must also be critically evaluated in terms of safety. For HIV-infected individuals, however, potential drug-drug interactions between antiretroviral therapy and rifampin or rifapentine must be a consideration. In South Africa, serious adverse events occurred at 8. When weekly rifapentine/INH for 12 weeks was compared with daily INH for 9 months among a largely HIVuninfected population, however, safety results were somewhat mixed. There was greater hepatoxicity in the INH group, but higher rates of permanent drug discontinuation due to an adverse event in the rifapentine/INH group (4.9 % vs. 3.7 %). This was thought to be due in part to a possible hypersensitivity reaction; however, a potential confounder could have been the more frequent interaction of participants with study staff in this arm, given that this arm was administered via directly-observed therapy [16••] . Hypersensitivity reactions had not been previously reported with rifapentine/INH regimen. Of note, this study had very few HIV-infected individuals and further data regarding safety in the HIV-infected participants are forthcoming.
Role of Tuberculin Skin Test
The benefit (or lack thereof) of LTBI treatment according to tuberculin skin test result has been investigated previously. In the United States, HIV-infected individuals with anergy did not benefit from treatment of LTBI [26•] . In a recent systematic review of several different preventive regimens in HIV-infected individuals, there was a 62 % reduction in the risk of active TB for those who were skin test positive but no benefit for those who were skin test negative [4] . The lack of benefit of INH preventive therapy in tuberculin skin test-negative individuals seen in the Botswana trial (and the possible trend toward increased mortality for those who received continuous INH and were skin test negative), leads some to suggest that the 2011 WHO recommendation for INH preventive therapy regardless of skin test result should be reevaluated [27] .
Duration of Protective Effect and Possible Reinfection
For those without HIV infection, INH provides protection against active TB for up to 19 years [28] . However, the duration of protective effect of any regimen depends on host factors (e.g., immune status), and on the prevalence of TB in the region. In high incidence settings, increased rates of TB seen following treatment of LTBI may be due to either reinfection or to activation of partially treated M. tuberculosis. However, few trials have assessed duration of protective effect, and the data are limited by duration of follow-up for these studies [4] . One study suggested that for HIVinfected individuals with positive skin tests in Uganda the duration of protective effect was for only 1 year after receiving 6 months of INH. The protective effect was approximately 3 years for a 3-month regimen of INH, rifampicin, and pyrazinamide, or 3 months of INH and rifampicin [13] . In Zambia, the protective effect of two different regimens (6 months of INH or 3 months of rifampicin plus pyrazinamide) in HIV-infected adults was approximately 2.5 years [12] . In another Zambian study of 6 months of INH versus 3 months of rifampicin plus pyrazinamide (both taken twice weekly), both arms had rates of TB similar to those in the placebo group at 18 months [29] .
In the 2011 trial in Botswana, increasing rates of TB were observed at just over 6 months after completion of 6INH when compared to 36 H [14••]. However, in South Africa, rates of TB increased after discontinuation of continuous INH as well (≤6 years) [15••] . When 3 months of rifapentine/INH were compared to 9INH, almost all cases of TB in the rifapentine/INH arm occurred during the first 500 days; only one case occurred in the second 500 days of follow-up. In the 9INH arm of this study, TB cases occurred throughout the follow-up period [30] . There has not yet been a comparison of the duration of protection of 3 months of rifapentine/ INH versus 36 H. Rifapentine-containing regimens may have greater sterilizing activity than regimens containing isoniazid alone, which could influence duration of protection.
Drug Resistance
One key potential concern is drug resistance among those who develop active TB after completing preventive therapy. In the Botswana trial of 6INH versus 36INH, 5 of the 29 cases of TB for which drug susceptibility testing was available were INH resistant; this was not thought to differ from expected rates of drug resistance in the region [14••] . In the South African study of rifapentine/INH or rifampin/INH (both for 12 weeks) versus INH-only containing regimens, there was one case of INH-resistant TB, 2 cases of rifampin-resistant TB, and one case resistant to both INH and rifampin in the rifapentine/INH group. Again, the overall rate of drugresistant TB in this study was comparable to that found elsewhere in the area [15••] . Though there were few HIVinfected individuals in the trial comparing weekly rifapentine plus INH versus 9 months of INH, one case of rifampinresistant TB occurred and it was in a HIV-infected person randomized to the rifapentine plus INH arm [16••] . This was a case of M. bovis, resistant to pyrazinamide (which is characteristic of M. bovis) as well as rifampin.
So what can be made of the resistance data from these trials? Other studies suggest that those who develop TB after INH preventive therapy do not appear to have an increased risk of resistance to INH [31] . In a systematic review of those receiving INH preventive therapy who subsequently developed TB, the relative risk of INH resistance was 1.45 (95 % CI 0.85-2.47), with similar results for both HIVinfected and HIV-uninfected individuals [32] . However, for those on rifamycin-containing preventive regimens, there may be more reason to give pause-particularly if the patient did not have latent infection but instead had active disease that was not suspected or detected. This is possible given the frequent occurrence of asymptomatic or subclinical tuberculosis in HIV-infected persons [33] . In a study of weekly INH/rifapentine (600 mg dose) for the continuation phase of active TB treatment, among HIVinfected individuals there were more relapses of TB disease when compared with those who received twice-weekly INH and rifampin in the continuation phase. Of those who relapsed in the weekly INH/rifapentine group, 4 of 5 had rifamycin resistance [34] . The risk of rifamycinresistance developing in INH/rifapentine preventive regimens may be due to a "pharmacokinetic mismatch." In a pharmacokinetic study of weekly rifapentine in patients with TB, 54 % of patients had detectable rifapentine levels 36 h after clearance of INH, when both drugs were given at the same time [35] .
Because of the overall low burden of organisms in LTBI, the risk of selecting for drug-resistance is likely low. However, the critical factor is ruling out active disease before starting preventive therapy. If active TB disease is missed and preventive therapy is initiated, the higher burden of organisms will increase the likelihood of selecting for drug-resistance. The WHO system for symptom-based screening (ruling out cough, fever, weight loss, and night sweats) had a negative predictive value of 97.7 % for active TB in settings where TB prevalence among HIV-infected individuals was at least 5 % [36] , and should aid clinicians in assessing for active disease prior to starting preventive therapy. As rifamycincontaining short-course preventive regimens are embraced, prevention of drug-resistance will hinge on ruling out active disease.
What These Studies Add
In considering the issues above, the three studies published in 2011 of different regimens for the treatment of LTBI demonstrate a few key points. Thirty-six months of INH was more effective than 6 months of INH only among HIVinfected persons with positive tuberculin skin tests [ However, safety will have to be closely monitored as this regimen is given to a broader population. The effectiveness and tolerability of this regimen will also need to be evaluated more closely in HIV-infected persons. One advantage of the once or twice-weekly rifamycin-based regimens is higher completion rates; a disadvantage is the requirement of directly-observed therapy. The Centers for Disease Control (CDC) has now recommended the use of once-weekly rifapentine and INH for 12 weeks for the treatment of LTBI as an alternative to 9INH in the United States [37] . However, this regimen is not recommended for HIV-infected persons receiving antiretroviral therapy, due to concerns regarding drug interactions with rifapentine [38] .
Unresolved Issues
Many questions remain about the preventive therapy regimens discussed here. Additional data are needed on the ability to implement the once-weekly rifapentine/INH regimen. While this regimen was given via directly-observed therapy, it will be important to assess in clinical trials whether it can be given as self-administered therapy. Though convenience would be increased via self-administration, this may lead to lower treatment completion rates and therefore lower effectiveness. Finally, there are numerous studies on cost-effectiveness of various LTBI regimens [39, 40] . None of these cost-effectiveness analyses, however, have focused specifically on M. tuberculosis preventive regimens for HIVinfected individuals, and information on this unique patient population is needed.
Conclusions
Three studies in 2011 examined regimens for the treatment of latent tuberculosis infection in HIV-infected adults. Shorter, rifamycin-based regimens given under direct observation have the advantage of greater adherence. Longer regimens of INH may decrease the risk of subsequent TB that has been seen with just 6 months of INH, but the benefit wanes shortly after INH is discontinued. When deciding on the optimal regimen, however, efficacy and safety are paramount. The role of tuberculin skin testing, the contribution of antiretroviral therapy, the emergence of resistance, and cost-effectiveness data will all be important when identifying the optimal regimen for HIV-infected individuals. While the regimens highlighted in 2011 hold promise, further evaluation is needed as they are used for the treatment of HIV-infected persons with latent M. tuberculosis infection.
